CervoMed generated $4.0M in revenue in fiscal year 2025. This represents a decrease of 58.9% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $331K in revenue. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters CervoMed has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
CRVO Revenue by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
CRVO Revenue by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What revenue means
Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.
More CervoMed financials
Frequently Asked Questions
What was CervoMed's revenue in fiscal year 2025?
CervoMed generated $4.0M in revenue in fiscal year 2025.
How fast is CervoMed's revenue growing?
CervoMed (CRVO) revenue fell by 58.9% year over year, from $9.7M to $4.0M in fiscal year 2025.
What is CervoMed's revenue over the last twelve months?
CervoMed (CRVO) reported $331K in revenue over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has CervoMed's revenue changed over the years?
Across the 15 fiscal years this page covers, CervoMed (CRVO) revenue went from $570K in fiscal year 2011 to $4.0M in fiscal year 2025.
What was CervoMed's revenue in the most recent quarter?
CervoMed (CRVO) reported $0 in revenue in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
What does revenue mean on a financial statement?
Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what CervoMed (CRVO) reported on that line in every period on record.